This notion had been recently reinforced by the finding that 24 weeks of acarbose monotherapy in newly diagnosed patients with T2DM was associated with increased levels of both fasting and postprandial glucagon-like peptide 1 (GLP-1), NO levels, and nitric oxide synthase (NOS) activity [21]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.